Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 12/20 | 0.68 |
| ▸ | PRLHR | P49683 | 6/20 | 0.68 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.65 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.62 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.62 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.62 |
| ▸ | CALCR | P30988 | 1/20 | 0.62 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366836 | 0.90 | HCRTR1 (0.68) | NPY2RPRLHRRAMP1RAMP2RAMP3 | |
| Davalintide SCHEMBL29533482 | 0.81 | RAMP1 (0.77) | NPY2RPRLHRINSRRAMP1RAMP2 | |
| SCHEMBL33618 | 0.80 | INSR (0.75) | NPY2RPRLHRNPFFR2INSR | |
| SCHEMBL15669703 | 0.80 | INSR (0.95) | NPY2RINSR | |
| SCHEMBL30888738 | 0.80 | NPY2R (0.63) | NPY2RINSRRAMP1RAMP2RAMP3 | |
| SCHEMBL14840198 | 0.80 | INSR (0.93) | NPY2RINSRRAMP1RAMP2RAMP3 | |
| SCHEMBL63125 | 0.79 | INSR (0.98) | NPY2RINSR | |
| SCHEMBL29511605 | 0.79 | RAMP1 (0.71) | NPY2RPRLHRINSRRAMP1RAMP2 | |
| Calcitonin Salmon SCHEMBL269785 | 0.78 | INSR (0.64) | NPY2RINSRRAMP1RAMP2RAMP3 | |
| SCHEMBL374892 | 0.78 | RAMP1 (0.78) | NPY2RPRLHRNPFFR2INSRRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-20250325760-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION | APTARGROUP INC. (US) | 2025-10-23 | — | — | US | claimed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137359-A1 | ASSAY METHODS TO IDENTIFY A DISEASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-06-26 | — | — | WO | claimed |
| US-12329902-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization | SIPNOSE LTD. (IL) | 2025-06-17 | — | — | US | claimed |
| CN-119587679-A | Use of Orexin-A for inhibiting lipid peroxidation | 贵州医科大学附属医院 | 2025-03-11 | — | — | CN | claimed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-20240180972-A1 | HUMAN PLURIPOTENT STEM CELL-DERIVED SECRETOME AS A BIOLOGIC FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE AND APOPTOTIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-06 | — | — | US | claimed |
| US-11992604-B2 | Devices and methods for delivering a substance to a body cavity | SIPNOSE LTD. (IL) | 2024-05-28 | — | — | US | claimed |
| EP-4243993-A1 | DEVICES AND METHODS FOR DELIVERING A SUBSTANCE TO A BODY CAVITY | Sipnose Ltd (IL) | 2023-09-20 | — | — | EP | claimed |
| US-11730904-B2 | Intranasal administration | Optinose, Inc. (US) | 2023-08-22 | — | — | US | claimed |
| US-11707586-B2 | Intranasal administration | OptiNose Inc. (US) | 2023-07-25 | — | — | US | claimed |
| EP-4114485-A1 | DEVICES AND METHODS FOR DELIVERING A SUBSTANCE TO A BODY CAVITY | Sipnose Ltd (IL) | 2023-01-11 | — | — | EP | claimed |
| WO-2022212878-A1 | HUMAN PLURIPOTENT STEM CELL-DERIVED SECRETOME AS A BIOLOGIC FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE AND APOPTOTIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022101851-A1 | DEVICES AND METHODS FOR DELIVERING A SUBSTANCE TO A BODY CAVITY | SIPNOSE LTD. (IL) | 2022-05-19 | — | — | WO | claimed |
| WO-2022101850-A1 | DEVICES AND METHODS FOR DELIVERING A SUBSTANCE TO A BODY CAVITY | SIPNOSE LTD. (IL) | 2022-05-19 | — | — | WO | claimed |
| US-20220032021-A1 | DEVICES AND METHODS FOR DELIVERING A SUBSTANCE TO A BODY CAVITY | SIPNOSE LTD. (IL) | 2022-02-03 | — | — | US | claimed |
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | disclosed |
| CN-109988169-B | Octahydropyrrolo [3,4-c ] pyrrole derivatives and uses thereof | 广东东阳光药业有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | NPY2R 25/4885PRLHR 632/4885NPFFR2 334/4885 |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | GCG, VAPA, GABRG2 | NPY2R 207/4885PRLHR 210/4885NPFFR2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.